$88.7M in CY2024 Part D spend3.6M claims · 1.0M beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Methotrexate used for?
a diydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ....
Is there a generic for Methotrexate?
Yes. 34 ANDAs filed at FDA, 14 generic manufacturers currently shipping.
How much does my plan pay for Methotrexate?
Across 329 Part D plans, Methotrexate averages $0.243/unit (NADAC). Lowest available: $0.158/unit. Highest in distribution: $1.21/unit.
Is Methotrexate on the FDA shortage list?
Yes. Methotrexate is currently listed as an active FDA shortage.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.